Last reviewed · How we verify
Amlodipine plus Metformin
This combination reduces blood pressure through calcium channel blockade (amlodipine) while improving glucose control through enhanced insulin sensitivity and reduced hepatic glucose production (metformin).
This combination reduces blood pressure through calcium channel blockade (amlodipine) while improving glucose control through enhanced insulin sensitivity and reduced hepatic glucose production (metformin). Used for Hypertension with type 2 diabetes mellitus, Cardiovascular risk reduction in patients with concurrent hypertension and hyperglycemia.
At a glance
| Generic name | Amlodipine plus Metformin |
|---|---|
| Sponsor | Third Military Medical University |
| Drug class | Combination therapy: calcium channel blocker + biguanide antidiabetic |
| Target | L-type voltage-gated calcium channels (amlodipine); AMP-activated protein kinase and mitochondrial glycerophosphate dehydrogenase (metformin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular and Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that relaxes vascular smooth muscle to lower blood pressure. Metformin is a biguanide that decreases hepatic gluconeogenesis and increases peripheral glucose uptake, improving insulin sensitivity. Together, they address both hypertension and hyperglycemia in patients with concurrent cardiovascular and metabolic disease.
Approved indications
- Hypertension with type 2 diabetes mellitus
- Cardiovascular risk reduction in patients with concurrent hypertension and hyperglycemia
Common side effects
- Peripheral edema
- Headache
- Flushing
- Gastrointestinal disturbance (metformin-related)
- Dizziness
- Lactic acidosis (rare, metformin-related)
Key clinical trials
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) (PHASE2)
- Nutraceuticals and Drug Treatment in Frail Older Adults
- Gut Microbiomes in Patients With Metabolic Syndrome
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine plus Metformin CI brief — competitive landscape report
- Amlodipine plus Metformin updates RSS · CI watch RSS
- Third Military Medical University portfolio CI